Last reviewed · How we verify
NCT06620263: guideline
Stress Ulcer Prophylaxis Practices in the Intensive Care Unit
trial testing Pre-education period (PreEd) in Stress Ulcer Prophylaxis in 495 participants. Completed in 3 July 2024.
3 July 2024
Quick facts
| Lead sponsor | Yunus Emre AYHAN |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 495 |
| Start date | 1 January 2024 |
| Primary completion | 3 July 2024 |
| Estimated completion | 3 July 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Pre-education period (PreEd)
- Post-education period (PostEd)
Conditions studied
- Stress Ulcer Prophylaxis — all drugs for Stress Ulcer Prophylaxis →
Sponsor
Yunus Emre AYHAN
Who can join
18 and older, any sex, with Stress Ulcer Prophylaxis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study aimed to examine the adherence of proton pump inhibitors (PPIs), commonly recommended for stress ulcer prevention (SUP) in patients in the intensive care unit (ICU), according to an international guideline. The objective of the study was to enhance the adherence of SUP prescriptions to the guideline, therefore preventing potential adverse effects and avoidable financial burden, and, consequently, attaining cost reduction.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06620263
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06620263 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yunus Emre AYHAN
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06620263.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing